Key result
PA pressure-guided management reduces HF hospitalizations ~28% vs control in HFrEF.
Why the study?
Despite guideline-directed medical therapy, some HFrEF patients remain at high risk for hospitalization and mortality, prompting investigation into whether PA pressure-guided management improves outcomes based on tolerance of GDMT.
Does pulmonary artery pressure-guided heart failure management reduce heart failure hospitalization and mortality in patients with HFrEF?
RCT (n=550)
Does pulmonary artery pressure-guided heart failure management reduce heart failure hospitalization and mortality in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“A post-hoc analysis of HFrEF patients in the CHAMPION trial showed the greatest benefit of PAP-guided therapy to decrease HFH and mortality in subjects who were taking both ACEI/ARB and beta blockers (hazard ratio 0.57 for HFH, 0.43 for mortality)”
“The present analysis confirms what was known from the CHAMPION trial, which created the evidence base for utilization of this technology: Hemodynamic monitoring reduces hospitalizations in all HF, regardless of EF.”
“the benefit of hemodynamic-guided management was primarily due to a 28% reduction in heart failure hospitalizations, the same reduction previously shown in the CHAMPION trial”
Pulmonary artery pressure-guided management significantly reduces heart failure hospitalizations in patients with HFrEF, with greater benefits observed in those receiving optimal guideline-directed medical therapy.
BACKGROUND: Despite increased use of guideline-directed medical therapy (GDMT), some patients with heart failure and reduced ejection fraction (HFrEF) remain at high risk for hospitalization and mortality. Remote monitoring of pulmonary artery (PA) pressures provides clinicians with actionable information to help further optimize medications and improve outcomes. OBJECTIVES: CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients trial) analyzed PA pressure-guided heart failure (HF) management in patients with HFrEF based on their ability to tolerate GDMT. METHODS: CHAMPION enrolled 550 patients with chronic HF regardless of left ventricular ejection fraction. A pre-specified sub-group analysis compared HF hospitalization and mortality rates between treatment and control groups in HFrEF patients (left ventricular ejection fraction ≤40%). Post hoc analyses in patients who tolerated GDMT were also performed. Hospitalizations and mortality were assessed using Andersen-Gill and Cox proportional hazards models. RESULTS: In 456 patients with HFrEF, HF hospitalization rates were 28% lower in the treatment group than in the control group (hazard ratio [HR]: 0.72; 95% confidence interval [CI]: 0.59 to 0.88; p = 0.0013), with a strong trend for 32% lower mortality (HR: 0.68; 95% CI: 0.45 to 1.02; p = 0.06). A 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-blocker) at baseline; these patients had 33% lower HF hospitalization rates (HR: 0.67; 95% CI: 0.54 to 0.82; p = 0.0002) and 47% lower mortality (HR: 0.63; 95% CI: 0.41 to 0.96, p = 0.0293) than controls. Compared with controls, patients receiving both components of optimal GDMT (n = 337) had 43% lower HF hospitalizations (HR: 0.57; 95% CI: 0.45 to 0.74; p < 0.0001) and 57% lower mortality (HR: 0.43; 95% CI: 0.24 to 0.76; p = 0.0026). CONCLUSIONS: PA pressure-guided HF management reduces morbidity and mortality in patients with HFrEF on GDMT, underscoring the important synergy of addressing hemodynamic and neurohormonal targets of HF therapy. (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients [CHAMPION]; NCT00531661).
No takes yet. Share an insight, caveat, or question.
Givertz et al. (2017) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) (n=550). Pulmonary artery pressure-guided heart failure management vs. Control group was evaluated on Heart failure hospitalization (HR 0.72, 95% CI 0.59-0.88, p=0.0013). In patients with HFrEF, pulmonary artery pressure-guided management reduced heart failure hospitalization rates by 28% compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: